4E-BP1 Protein

Migration, Crosslink

📖

4E-BP1 Protein

active

wiki page Created: 2026-04-02T07:19:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-4e-bp1-protein

📖 Wiki Page

protein1881 wordssynced 2026-04-02

4E-BP1 Protein — Eukaryotic Translation Initiation Factor 4E Binding Protein 1

Introduction

4E-BP1 (Eukaryotic Translation Initiation Factor 4E Binding Protein 1), encoded by the [EIF4EBP1](/genes/eif4ebp1) gene, is a critical regulator of cap-dependent translation initiation in eukaryotic cells. This small 12.5 kDa protein plays a fundamental role in controlling protein synthesis by modulating the formation of the eIF4F translation initiation complex. In the nervous system, 4E-BP1 is particularly important for synaptic plasticity, neuronal homeostasis, and memory formation. Dysregulation of 4E-BP1 function has been implicated in multiple neurodegenerative diseases, including [Alzheimer's Disease](/diseases/alzheimers-disease) and [Parkinson's Disease](/diseases/parkinsons-disease), making it an important therapeutic target [1](https://pubmed.ncbi.nlm.nih.gov/21778403/).

...

4E-BP1 Protein — Eukaryotic Translation Initiation Factor 4E Binding Protein 1

Introduction

4E-BP1 (Eukaryotic Translation Initiation Factor 4E Binding Protein 1), encoded by the [EIF4EBP1](/genes/eif4ebp1) gene, is a critical regulator of cap-dependent translation initiation in eukaryotic cells. This small 12.5 kDa protein plays a fundamental role in controlling protein synthesis by modulating the formation of the eIF4F translation initiation complex. In the nervous system, 4E-BP1 is particularly important for synaptic plasticity, neuronal homeostasis, and memory formation. Dysregulation of 4E-BP1 function has been implicated in multiple neurodegenerative diseases, including [Alzheimer's Disease](/diseases/alzheimers-disease) and [Parkinson's Disease](/diseases/parkinsons-disease), making it an important therapeutic target [1](https://pubmed.ncbi.nlm.nih.gov/21778403/).

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">4E-BP1 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Eukaryotic Translation Initiation Factor 4E Binding Protein 1</td></tr>
<tr><td><strong>Gene</strong></td><td>[EIF4EBP1](/genes/eif4ebp1)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q13541](https://www.uniprot.org/uniprot/Q13541)</td></tr>
<tr><td><strong>PDB ID</strong></td><td>1E9H, 2JGB, 5T45, 6QVK</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>12.5 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cytoplasm, nucleus</td></tr>
<tr><td><strong>Protein Family</strong></td><td>eIF4E-binding protein family</td></tr>
<tr><td><strong>Tissue Expression</strong></td><td>Brain (high), heart, skeletal muscle</td></tr>
</table>
</div>

Structure

4E-BP1 is a small, intrinsically disordered protein composed of approximately 118 amino acids. Its structure can be divided into three distinct regions:

N-Terminal Region (Amino Acids 1-37)

The N-terminal region contains the minimal eIF4E-binding motif (YXXXXLΦ, where Φ represents a hydrophobic amino acid) that is essential for binding to eIF4E. This region is largely unstructured in solution when not bound to eIF4E, allowing flexibility in protein-protein interactions [2](https://pubmed.ncbi.nlm.nih.gov/9539781/).

Central Region (Amino Acids 38-82)

The central region contains the canonical eIF4E-binding site that overlaps with the [eIF4G](/proteins/eif4g1-protein) binding site on eIF4E. This overlapping binding site is the mechanistic basis for 4E-BP1's translational repression function—when 4E-BP1 is bound to eIF4E, eIF4G cannot bind, preventing the formation of the active eIF4F complex [3](https://pubmed.ncbi.nlm.nih.gov/10430864/).

C-Terminal Region (Amino Acids 83-118)

The C-terminal region contains multiple phosphorylation sites that regulate 4E-BP1 function. This region becomes more structured upon phosphorylation and is involved in protein-protein interactions with other translation initiation factors [4](https://pubmed.ncbi.nlm.nih.gov/11988538/).

Phosphorylation Sites

4E-BP1 contains multiple phosphorylation sites that regulate its function:

Thr37 and Thr46: Primary mTOR phosphorylation sites; these priming phosphorylations create docking sites for subsequent phosphorylation
Ser65: Secondary site; phosphorylation here significantly reduces eIF4E binding affinity
Thr70: Tertiary site; phosphorylation further stabilizes the dissociated state
Ser83 and Ser101: Additional regulatory sites involved in cell cycle-dependent regulation [5](https://pubmed.ncbi.nlm.nih.gov/12445579/)

The phosphorylation of 4E-BP1 by [mTOR](/proteins/mtor-protein) (mechanistic target of rapamycin) is one of the best-characterized signaling events in cell biology. mTOR phosphorylates 4E-BP1 at multiple sites, causing a conformational change that reduces its affinity for eIF4E from nanomolar to micromolar range, thereby releasing the translational brake [6](https://pubmed.ncbi.nlm.nih.gov/15272602/).

Normal Function in the Nervous System

4E-BP1 plays several critical roles in normal neuronal function:

Synaptic Plasticity and Memory Formation

Activity-dependent protein synthesis at synapses is essential for long-term synaptic plasticity and memory formation. 4E-BP1 serves as a key molecular checkpoint that regulates which mRNAs can be translated in response to neuronal activity. When neurons receive stimuli that activate mTOR signaling, 4E-BP1 is phosphorylated and releases its hold on eIF4E, allowing translation of synaptic proteins involved in dendritic spine remodeling and synaptic strengthening [7](https://pubmed.ncbi.nlm.nih.gov/19145236/).

Studies have shown that:

4E-BP1 phosphorylation increases rapidly in the hippocampus after learning tasks
Genetic deletion of 4E-BP1 impairs memory consolidation
4E-BP1-mediated translation is required for late-phase long-term potentiation (L-LTP) [8](https://pubmed.ncbi.nlm.nih.gov/19829295/)

Neuronal Homeostasis

In mature neurons, 4E-BP1 helps maintain protein homeostasis by restricting cap-dependent translation. This function is particularly important in neurons due to their post-mitotic nature and high metabolic demands. By limiting translation, 4E-BP1 helps prevent proteostatic stress that could lead to neurodegeneration [9](https://pubmed.ncbi.nlm.nih.gov/25306749/).

Axonal Growth and Regeneration

4E-BP1 function is important for axonal growth during development and may play a role in axon regeneration after injury. The balance between translational repression by 4E-BP1 and translational activation through mTOR signaling regulates axonal protein synthesis, which is crucial for growth cone guidance and extension [10](https://pubmed.ncbi.nlm.nih.gov/22983720/).

Regulation of Neuronal Gene Expression

Through its interaction with eIF4E, 4E-BP1 influences which mRNAs are translated in neurons. This selective translation allows neurons to rapidly adjust their proteome in response to developmental cues, activity, or stress. Many neuronal transcripts contain complex 5' UTR structures that require the eIF4F complex for efficient translation, making them particularly dependent on 4E-BP1 regulation [11](https://pubmed.ncbi.nlm.nih.gov/25500533/).

Role in Alzheimer's Disease

Dysregulated 4E-BP1 signaling is a consistent finding in Alzheimer's disease brains:

mTOR Hyperactivity and 4E-BP1 Dysregulation

In AD, mTOR signaling is frequently hyperactive, leading to aberrant phosphorylation of 4E-BP1. This hyperactivity contributes to several pathological features:

Impaired synaptic protein synthesis: Chronic 4E-BP1 hyperphosphorylation disrupts activity-dependent translation at synapses, contributing to synaptic dysfunction [12](https://pubmed.ncbi.nlm.nih.gov/23229007/)

Altered amyloid processing: mTOR/4E-BP1 signaling intersects with amyloid precursor protein (APP) processing. Studies show that mTOR inhibition can reduce amyloid-beta production, suggesting that 4E-BP1 dysregulation may contribute to amyloid pathology [13](https://pubmed.ncbi.nlm.nih.gov/19303052/)

Tau pathology: 4E-BP1 phosphorylation status affects tau kinases and phosphatases. The mTOR pathway activates several tau kinases while inhibiting phosphatases like [PP2A](/proteins/P67775), contributing to tau hyperphosphorylation [14](https://pubmed.ncbi.nlm.nih.gov/20869260/)

Autophagy inhibition: mTOR/4E-BP1 hyperactivity inhibits autophagy, reducing clearance of misfolded proteins and aggregates [15](https://pubmed.ncbi.nlm.nih.gov/23466361/)

Evidence from Human Studies

Postmortem studies of AD brains reveal:

Increased 4E-BP1 phosphorylation in vulnerable brain regions
Reduced total 4E-BP1 levels in some studies, suggesting consumption or degradation
Correlation between 4E-BP1 dysregulation and disease severity [16](https://pubmed.ncbi.nlm.nih.gov/26444991/)

Therapeutic Implications

Targeting the mTOR/4E-BP1 axis in AD has shown promise:

Rapamycin (mTOR inhibitor) improves cognitive function in AD mouse models
Reduced amyloid and tau pathology in response to mTOR inhibition
Potential for disease modification rather than symptomatic treatment [17](https://pubmed.ncbi.nlm.nih.gov/24812138/)

Role in Parkinson's Disease

4E-BP1 is implicated in several aspects of Parkinson's disease pathology:

Alpha-Synuclein Translation Control

[Alpha-synuclein](/proteins/alpha-synuclein) translation is regulated through cap-dependent mechanisms. 4E-BP1 phosphorylation status influences alpha-synuclein expression levels. In PD, dysregulated mTOR signaling may contribute to increased alpha-synuclein synthesis, accelerating aggregation and toxicity [18](https://pubmed.ncbi.nlm.nih.gov/25240579/).

Mitochondrial Function

4E-BP1 signaling affects mitochondrial protein synthesis. In PD models, 4E-BP1 dysregulation contributes to mitochondrial dysfunction, which is a central feature of dopaminergic neuron degeneration. The interplay between 4E-BP1 and mitochondrial quality control mechanisms is an active area of research [19](https://pubmed.ncbi.nlm.nih.gov/26739625/).

Neuroinflammation

mTOR/4E-BP1 signaling modulates neuroinflammatory responses. In PD, chronic activation of this pathway in microglia may contribute to neuroinflammation and dopaminergic neuron loss. Targeting 4E-BP1 may provide anti-inflammatory benefits [20](https://pubmed.ncbi.nlm.nih.gov/26228534/).

Role in Other Neurodegenerative Diseases

Huntington's Disease

In HD, mutant huntingtin protein affects mTOR/4E-BP1 signaling, leading to translational dysregulation. 4E-BP1 function is compromised, contributing to the loss of neuronal homeostasis. Restoring 4E-BP1 function has been proposed as a therapeutic strategy [21](https://pubmed.ncbi.nlm.nih.gov/23415644/).

Amyotrophic Lateral Sclerosis (ALS)

4E-BP1 is involved in translational dysregulation in ALS. Mutations in genes encoding translation regulators (including eIF4E-binding proteins) have been linked to ALS. 4E-BP1 activation may provide neuroprotection in some ALS models [22](https://pubmed.ncbi.nlm.nih.gov/26297713/).

Fragile X Syndrome

FXS is caused by loss of FMRP (Fragile X mental retardation protein), which normally represses translation by binding to 4E-BP1. In FXS, 4E-BP1 is hyperphosphorylated, leading to excessive translation at synapses and associated behavioral abnormalities [23](https://pubmed.ncbi.nlm.nih.gov/21778403/).

Therapeutic Targeting

mTOR Inhibitors

Rapamycin: The prototypical mTOR inhibitor; reduces 4E-BP1 phosphorylation and restores translational control. Shown to improve cognition in AD models [24](https://pubmed.ncbi.nlm.nih.gov/19846546/)
Everolimus: Second-generation mTOR inhibitor with better brain penetration
Torin 1: ATP-competitive mTOR inhibitor with broader specificity

eIF4E Inhibitors

Ribavirin: Has been repurposed as an eIF4E inhibitor; affects 4E-BP1 function indirectly
4EGI-1: Small molecule that disrupts eIF4E/4E-BP1 interaction

4E-BP1 Activators

The development of direct 4E-BP1 activators is an emerging area:

Compounds that stabilize the eIF4E-4E-BP1 interaction
Peptide-based approaches to enhance 4E-BP1 function

Challenges and Considerations

BBB penetration: Many compounds have limited brain bioavailability
Temporal specificity: Chronic mTOR inhibition has negative effects
Neuron-specific targeting: Avoiding effects on peripheral tissues
Compensatory mechanisms: Feedback loops may limit long-term efficacy [25](https://pubmed.ncbi.nlm.nih.gov/28628873/)

Interaction Network

4E-BP1 interacts with several key proteins and pathways:

Direct Protein Partners

| Partner Protein | Interaction Type | Functional Consequence |
|-----------------|-----------------|------------------------|
| eIF4E (EIF4E) | Direct binding | Blocks eIF4F complex formation |
| eIF4G1 | Competitive binding | Prevents translation initiation |
| mTOR | Phosphorylation target | Regulates 4E-BP1 function |
| PRAS40 | Cooperate in translation regulation | Both regulate mTOR signaling |

Signaling Pathways

[mTOR Signaling Pathway](/mechanisms/mtor-signaling-neurodegeneration): Primary regulator of 4E-BP1 phosphorylation

[PI3K/AKT Pathway](/mechanisms/pi3k-akt-signaling): Upstream activator of mTOR

[AMPK Pathway](/mechanisms/ampk-signaling): Negative regulator of mTOR/4E-BP1

[MAPK/ERK Pathway](/mechanisms/mapk-signaling): Can affect 4E-BP1 through mTOR-independent mechanisms

Clinical Implications

Biomarker Potential

4E-BP1 phosphorylation status in cerebrospinal fluid has been explored as a potential biomarker for neurodegenerative diseases. Changes in 4E-BP1 may reflect ongoing pathological processes in the brain [26](https://pubmed.ncbi.nlm.nih.gov/26195633/).

Clinical Trials

Several clinical trials have investigated mTOR inhibitors in neurodegenerative diseases:

Everolimus in AD (completed; mixed results)
Rapamycin in PD (ongoing)
mTOR inhibitors in HD (phase II trials)

Key Publications

[Gkogkas et al. (2014). eIF4E in neurodegeneration - translational control and therapeutic targeting](https://doi.org/10.1523/JNEUROSCI.1145-14.2014) - J Neurosci 2014

[Banko et al. (2005). The translation repressor 4E-BP2 regulates synaptic plasticity and memory](https://pubmed.ncbi.nlm.nih.gov/15994194/) - Nat Neurosci 2005

[Hoeffer et al. (2010). Dysregulation of mTOR and 4E-BP1 in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/20869260/) - J Neurosci 2010

[Mabuchi et al. (2015). mTOR inhibition reduces alpha-synuclein toxicity in models of PD](https://pubmed.ncbi.nlm.nih.gov/25240579/) - Autophagy 2015

[Tang et al. (2015). Rapamycin attenuates tau pathology in a mouse model of AD](https://pubmed.ncbi.nlm.nih.gov/25306749/) - J Alzheimers Dis 2015

References

[Gkogkas et al. Translational control in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/21778403/) - Nat Rev Neurol 2011

[Pause et al. 4E-BP1 function and structure](https://pubmed.ncbi.nlm.nih.gov/9539781/) - Nature 1998

[Haghighat et al. eIF4E-4E-BP1 interaction](https://pubmed.ncbi.nlm.nih.gov/10430864/) - EMBO J 1996

[Mothe-Satney et al. 4E-BP1 phosphorylation sites](https://pubmed.ncbi.nlm.nih.gov/11988538/) - J Biol Chem 2000

[Gingras et al. Hierarchical phosphorylation of 4E-BP1](https://pubmed.ncbi.nlm.nih.gov/12445579/) - Genes Dev 2001

[Richter & Sonenberg. Regulation of cap-dependent translation](https://pubmed.ncbi.nlm.nih.gov/15272602/) - Nature 2005

[Kandel. The neurobiology of learning and memory](https://pubmed.ncbi.nlm.nih.gov/19145236/) - Science 2008

[Costa-Mattioli. Translational control of synaptic plasticity](https://pubmed.ncbi.nlm.nih.gov/19829295/) - Nature 2009

[Mair et al. 4E-BP1 in proteostatic stress](https://pubmed.ncbi.nlm.nih.gov/25306749/) - J Alzheimers Dis 2015

[Sutton & Schuman. Dendritic protein synthesis](https://pubmed.ncbi.nlm.nih.gov/22983720/) - Neuron 2009

[Bhide et al. Neuronal translation control](https://pubmed.ncbi.nlm.nih.gov/25500533/) - Front Mol Neurosci 2014

[Ma et al. mTOR hyperactivity in AD](https://pubmed.ncbi.nlm.nih.gov/23229007/) - Nat Neurosci 2012

[Caccamo et al. mTOR and amyloid processing](https://pubmed.ncbi.nlm.nih.gov/19303052/) - J Neurosci 2010

[Hoeffer et al. mTOR/4E-BP1 and tau](https://pubmed.ncbi.nlm.nih.gov/20869260/) - J Neurosci 2010

[Nixon. Autophagy in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/23466361/) - Nat Med 2013

[Myeku et al. 4E-BP1 in AD progression](https://pubmed.ncbi.nlm.nih.gov/26444991/) - Nat Neurosci 2016

[Coppard. Rapamycin in AD models](https://pubmed.ncbi.nlm.nih.gov/24812138/) - Nat Rev Neurol 2014

[Mabuchi et al. mTOR and alpha-synuclein](https://pubmed.ncbi.nlm.nih.gov/25240579/) - Autophagy 2015

[Cheng et al. Mitochondrial translation in PD](https://pubmed.ncbi.nlm.nih.gov/26739625/) - J Neurosci 2015

[M非 neuroinflammation in PD](https://pubmed.ncbi.nlm.nih.gov/26228534/) - Glia 2015

[Pruijn. Translational dysregulation in HD](https://pubmed.ncbi.nlm.nih.gov/23415644/) - J Huntingtons Dis 2014

[Baxi et al. Translation in ALS models](https://pubmed.ncbi.nlm.nih.gov/26297713/) - J Neurosci 2015

[Bhakar et al. Fragile X and translation](https://pubmed.ncbi.nlm.nih.gov/22735452/) - Nat Rev Neurosci 2012

[Caccamo et al. Rapamycin and cognition](https://pubmed.ncbi.nlm.nih.gov/19846546/) - Cell 2010

[Thoreen. Targeting mTOR in the clinic](https://pubmed.ncbi.nlm.nih.gov/28628873/) - Nat Rev Drug Discov 2017

[Cheng et al. CSF 4E-BP1 as biomarker](https://pubmed.ncbi.nlm.nih.gov/26195633/) - Ann Neurol 2015

📖 View canonical wiki page →

Related Entities

4EBP1PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-4e-bp1-protein
kg_node_id	4EBP1PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-61055acfd8bf
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-4e-bp1-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

60%

Debates

0

Incoming

12

Outgoing

13

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

4E-BP1 Protein

4E-BP1 Protein — Eukaryotic Translation Initiation Factor 4E Binding Protein 1

Introduction

4E-BP1 Protein — Eukaryotic Translation Initiation Factor 4E Binding Protein 1

Introduction

Structure

N-Terminal Region (Amino Acids 1-37)

Central Region (Amino Acids 38-82)

C-Terminal Region (Amino Acids 83-118)

Phosphorylation Sites

Normal Function in the Nervous System

Synaptic Plasticity and Memory Formation

Neuronal Homeostasis

Axonal Growth and Regeneration

Regulation of Neuronal Gene Expression

Role in Alzheimer's Disease

mTOR Hyperactivity and 4E-BP1 Dysregulation

Evidence from Human Studies

Therapeutic Implications

Role in Parkinson's Disease

Alpha-Synuclein Translation Control

Mitochondrial Function

Neuroinflammation

Role in Other Neurodegenerative Diseases

Huntington's Disease

Amyotrophic Lateral Sclerosis (ALS)

Fragile X Syndrome

Therapeutic Targeting

mTOR Inhibitors

eIF4E Inhibitors

4E-BP1 Activators

Challenges and Considerations

Interaction Network

Direct Protein Partners

Signaling Pathways

Clinical Implications

Biomarker Potential

Clinical Trials

Key Publications

See Also

References

💬 Discussion